Results 21 to 30 of about 2,622 (185)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

Rheumatology and Therapy, 2022
Plain Language Summary Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes.
Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin, Maya H. Buch   +6 more
doaj   +4 more sources

Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: analysis of the phase 2b/3 SELECTION study [PDF]

Intestinal Research
Background/Aims Obtaining and maintaining corticosteroid-free remission are important goals of treatment for ulcerative colitis (UC). Characteristics associated with achieving corticosteroid-free remission were assessed in filgotinib-treated patients in ...
Taku Kobayashi, Axel Dignass, Xavier Roblin, Yoshie Takatori, Toshihiko Kaise, Alessandra Oortwijn, Corinne Jamoul, Toshifumi Hibi   +7 more
doaj   +3 more sources

Filgotinib in Active Noninfectious Uveitis [PDF]

JAMA Ophthalmology
ImportanceNoninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.ObjectiveTo assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.Design, Setting, and ParticipantsThe HUMBOLDT trial was a double-masked, placebo ...
Srivastava, Sunil K, Watkins, Timothy R, Nguyen, Quan Dong, Sharma, Sumit, Scales, David K, Dacey, Mark S, Shah, Rajiv E, Chu, David S, Grewal, Dilraj S, Faia, Lisa J, Suhler, Eric B, Genovese, Mark C, Guo, Ying, Barchuk, William T, Besuyen, Robin, Dick, Andrew D, Rosenbaum, James T   +16 more
openaire   +7 more sources

Filgotinib for moderately to severely active ulcerative colitis [PDF]

Expert Review of Gastroenterology & Hepatology, 2022
Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci, Ferdinando D’Amico, Ahmad El Saadi, Laurent Peyrin-Biroulet, Silvio Danese   +4 more
openaire   +3 more sources

Filgotinib bei Colitis ulcerosa: ein Review [PDF]

Journal für Gastroenterologische und Hepatologische Erkrankungen
ZusammenfassungColitis ulcerosa ist eine chronisch entzündliche Darmerkrankung mit Befall des Kolons. Die häufigsten Symptome sind blutige und schleimige Durchfälle, Stuhldrang sowie abdominelle Schmerzen. Diese Symptome stellen für die Betroffenen oft eine wesentliche gesundheitliche Beeinträchtigung dar.Filgotinib ist ein Medikament, das in oraler ...
Blesl, Andreas, Novacek, Gottfried, Reinisch, Walter, Kienbauer, Melanie, Platzer, Reingard, Wolzt, Michael, Koch, Robert, Högenauer, Christoph, Ribarics, Reiner, Moschen, Alexander   +9 more
openaire   +3 more sources

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study [PDF]

RMD Open
Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.
Hendrik Schulze-Koops, Tsutomu Takeuchi, Daniel Aletaha, Maya H Buch, Yoshiya Tanaka, Ricardo Blanco, Paul Emery, Jacques-Eric Gottenberg, Bernard G Combe, Roberto Caporali, Patrick Verschueren, Vijay Rajendran, Anna Zubrzycka-Sienkiewicz, Edmund V Ekoka Omoruyi, Francesco De Leonardis   +14 more
doaj   +3 more sources

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective [PDF]

Intestinal Research
In real-world clinical practice, 3 Janus kinase (JAK) inhibitors—tofacitinib, filgotinib, and upadacitinib—are now available for the treatment of ulcerative colitis.
Shintaro Akiyama
doaj   +2 more sources

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes [PDF]

RMD Open
Objectives Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major adverse ...
Zoltan Szekanecz, Yoshiya Tanaka, Laurent Peyrin-Biroulet, Stefan Schreiber, René Westhovens, Xavier Mariette, Chris Watson, C Janneke van der Woude, Hugo ten Cate, Andreas Stallmach, Christina Charles-Schoeman, Sandrine Aspeslagh, Marc Schmalzing, Margaux Faes, Sven Borchmann, Christine Rudolph, Edmund V Ekoka Omoruyi, Paul Van Hoek, Ernest HS Choy, Tomasz Masior   +19 more
doaj   +3 more sources

Filgotinib: First Approval [PDF]

Drugs, 2020
Filgotinib (Jyseleca®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.
Dhillon, Sohita, Keam, Susan J.
openaire   +2 more sources

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and Translational Science, 2022
Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in
Chia‐Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A. Othman   +5 more
doaj   +1 more source